DefinitionThis section has been translated automatically.
Immunoregulatory active, genetically engineered, recombinant, unmodified form of the soluble TNF-alpha-receptor type I (p55).
Pharmacodynamics (Effect)This section has been translated automatically.
High affinity binding of soluble TNF-alpha receptor type 1 molecules to TNF-alpha. This neutralizes the bound TNF-alpha molecules and makes them physiologically ineffective.
Field of application/useThis section has been translated automatically.
Not yet approved at present. Hopeful substance in the pipeline. According to Phase II registration studies (manufacturer's data), it is effective in psoriasis vulgaris, psoriatic arthritis and Crohn's disease. The results of phase III and IV studies remain to be seen.
LiteratureThis section has been translated automatically.
- Gladman DD (2004) Psoriatic arthritis. Dermatol Ther 17: 350-363
- Nikas SN, Drosos AA (2003) Onercept. Serono. Curr Opin Investig Drugs 4: 1369-1376
Prof. Dr. med. Peter Altmeyer